Comments to FDA: Evaluating Drug Names for Similarities; Methods and Approaches

These comments are submitted in response to the public meeting of June 26 on evaluating drug names for similarities, which was co-sponsored by the FDA, PhRMA, and the Institute for Safe Medication Practices.